Ernexa Therapeutics Inc
ernexatx.comErnexa Therapeutics Inc (ERNA) is a preclinical-stage biotechnology company developing synthetic allogeneic iMSC-based cell therapies for cancer and autoimmune disease. The company has no product revenue as of its fiscal year ended December 31, 2025, operating entirely on capital raises to fund research and development. Its lead product candidate, ERNA-101, consists of allogeneic IL-7 and IL-15-secreting induced pluripotent stem cell-derived mesenchymal stem cells (iMSCs) designed to exploit the tumor-homing properties of MSCs. The initial target indication is platinum-resistant ovarian cancer. ERNA-101 remains in preclinical development, with no approved products and no commercialization revenue reported in the 10-K filed March 13, 2026. CEO Sanjeev Luther serves as President, Chief Executive Officer, and Director. Charles Cherington is the largest beneficial stockholder at 32.54% of common shares as of the filing date. The company conducted a 1-for-15 reverse stock split effective June 10, 2025, leaving 150 million authorized shares of common stock unchanged.
Products & Services
Lead product candidate ERNA-101: allogeneic IL-7 and IL-15-secreting iMSCs (iPSC-derived mesenchymal stem cells) targeting platinum-resistant ovarian cancer. Patent application FAB-023 covers methods for reprogramming and gene editing cells, including engineered chromatin opening sequences at DNA target sites. All programs are preclinical as of the fiscal year ended December 31, 2025.
Revenue Model
No product revenue. Ernexa Therapeutics is preclinical-stage and funds operations through equity issuances. No partnerships, royalties, or licensing revenues are disclosed in the 10-K filed March 13, 2026.
Customers & Markets
No commercial customers. Target end markets are oncology (initial indication: platinum-resistant ovarian cancer) and autoimmune disease. Future reimbursement would depend on Medicare, Medicaid, managed care organizations, private commercial health insurers, and pharmacy benefit managers.
Geographic Exposure
Incorporated in Delaware, regulated under U.S. FDA requirements. The 10-K filed March 13, 2026 references both U.S. and foreign regulatory pathways but discloses no operating presence outside the United States.
Financial Snapshot
Loading...
